JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.

The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.

Clinical Gastroenterology and Hepatology, published by Elsevier Science Inc, stands as a leading journal in the fields of gastroenterology and hepatology. With an ISSN of 1542-3565 and an E-ISSN of 1542-7714, this esteemed publication has earned its place in the top quartile (Q1) of both gastroenterology and hepatology categories as of 2023, ranking 6th out of 167 and 7th out of 82 respectively. The journal aims to disseminate innovative research, clinical studies, and case reports that advance the understanding and treatment of gastrointestinal and liver diseases. Targeted towards researchers, healthcare professionals, and students, it provides crucial insights into emerging therapies and medical advancements. Clinical Gastroenterology and Hepatology is not only a pivotal resource for contemporary gastroenterological research but also fosters collaboration and knowledge-sharing within the medical community. With a converging publication history from 2003 to the present, the journal continues to build on its solid foundation of scientific excellence and relevance.

The Egyptian Liver Journal, ISSN 2090-6218, is a vital resource for the hepatology community, published by SPRINGEROPEN. Since its establishment in 2012, this journal has served as a platform for disseminating significant findings in liver research, with an emphasis on enhancing understanding and treatment of liver diseases. Recognized with a Q3 ranking in Hepatology for 2023, the Egyptian Liver Journal aims to bridge the gap between research and clinical practice through its commitment to open access, fostering a global exchange of knowledge without barriers since 2019. With a focus on innovative studies, reviews, and clinical guidelines, the journal appeals to a diverse audience of researchers, clinicians, and students dedicated to advancing liver health. Situated in the heart of the United States, this publication addresses the pressing issues within the field and encourages submissions that address the future of liver care and treatment.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

JGH Open is a prominent open-access journal dedicated to advancing knowledge in the fields of Gastroenterology and Hepatology, published by WILEY. Since its inception in 2017, the journal has served as a crucial platform for researchers, professionals, and students to disseminate innovative research findings and clinical insights. With an impact factor and Scopus rankings reflecting its steady growth—ranking in the 3rd quartile for both Gastroenterology (Q3) and Hepatology (Q3)—JGH Open is positioned within the competitive landscape of medicine. Its commitment to open access enhances the visibility and accessibility of high-quality research, ensuring that significant advancements in understanding diseases of the gastrointestinal tract and liver reach a broad audience. With a focus on collaboration and dissemination of knowledge, JGH Open aims to contribute to the global discourse and improve outcomes in gastrointestinal health.

Cellular and Molecular Gastroenterology and Hepatology, published by Elsevier Inc, is a premier Open Access journal dedicated to advancing the understanding and treatment of gastrointestinal and liver diseases. Since its inception in 2015, this journal has established itself as a leading publication within its field, boasting impressive metrics with a 2023 Q1 ranking in both Gastroenterology and Hepatology. It ranks #10 out of 167 in Gastroenterology and #11 out of 82 in Hepatology on Scopus, placing it in the 94th and 87th percentiles, respectively. This journal aims to disseminate high-quality, peer-reviewed research that fosters innovative solutions for clinical challenges, making it an invaluable resource for researchers, healthcare professionals, and students alike. With open access, all published content is readily available to a global audience, ensuring that critical findings in cellular and molecular biology related to gastroenterology and hepatology reach those who can benefit the most from the latest advances in the field. For more information, please visit us at our address in San Diego, CA, or explore our articles online.

Clinics in Liver Disease is an esteemed peer-reviewed journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of hepatology. Established in 1997 and covering a broad range of topics within liver disease research, this journal serves as a vital resource for researchers, clinicians, and students engaged in the study of liver health and diseases. With a commendable impact factor placing it within the Q2 category in Hepatology and ranking #32 out of 82 in the Scopus classifications, it consistently disseminates high-quality research and clinical insights. The journal’s commitment to promoting understanding and management of liver diseases is reflected in its rigorous editorial standards and comprehensive review processes. Although not an open-access publication, Clinics in Liver Disease offers subscription options that ensure accessibility to up-to-date research and reviews critical for both academic and clinical success.